Scirama Psychedelic Science

Psychedelic compounds, historically documented in traditional contexts, represent a class of bioactive substances with significant therapeutic potential. When rigorously investigated through scientific and clinical research, these compounds may contribute to the development of novel treatment options for complex and underserved medical conditions. Scirama is a biotechnology-driven startup dedicated to Research, Development, and Innovation (R&D&I), with a strategic focus on the systematic study of psychedelic compounds. Operating within the science and technology innovation ecosystem, the company develops a structured portfolio through strategic partnerships with academic institutions, research centers, and industry stakeholders. Through this collaborative and science-based approach, Scirama aims to advance translational research and support the development of safe, effective, and evidence-based therapeutic solutions, with particular emphasis on mental health conditions that require more effective and innovative treatment strategies. Contact: contato@scirama.com